News
Sheer scale of ovarian cancer cost revealed in landmark report
The rising toll of ovarian cancer globally has been tracked in a new study – calculating a US$70bn financial burden to the 11 countries involved.
The World Ovarian Cancer Coalition set out to measure the major socioeconomic burden ovarian cancer has on communities around the world.
Its report shows the staggering US$70bn burden of the disease, with over 90 per cent of these costs resulting from lives lost.
The study examined data from a diverse group of countries representing a range of income levels: Australia, Canada, Colombia, India, Kazakhstan, Kenya, Nigeria, Malawi, Malaysia, the United Kingdom and the US.
The coalition’s CEO Clara MacKay said: “Behind these numbers, there are many untold stories of women’s lives being disrupted, facing severe financial hardship and stigma due to their ovarian cancer.
“We hope, and expect, that by shining a light on the impact of ovarian cancer, policy makers will commit to a formal plan to address the challenges faced by women and acknowledge that by supporting them, society as a whole can benefit.”
Ovarian cancer is one of the most lethal forms of cancer, with significantly low survival rates. According to Globocan’s 2022 projections, by 2050, the number of women around the world diagnosed with ovarian cancer will grow by 55 per cent. Without improved prevention and control measures, mortality will increase by 70 per cent.
The study’s findings underscore not only the moral and public health imperative to address ovarian cancer but also the urgent economic need to prioritise action.
The study highlights significant losses in labour productivity, estimating that 2.5 million workdays are lost annually due to ovarian cancer. Furthermore, more than 9,400 women are absent from the workforce due to the disease.
Caregivers, often overlooked in public health planning, dedicate an average of 33 days per year providing essential support to loved ones battling ovarian cancer.
Dr. Guy Fones, of the World Health Organisation, said: “The data from this groundbreaking study is essential to our understanding of the multifaceted socio-economic impact of ovarian cancer, a disease that has long been under-evidenced in the global health landscape. The World Health Organisation is committed to advancing data-backed strategies that prioritise equity and improve access to care and outcomes for all women no matter where they live.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur5 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health






